Skip to main content
Beta Drugs Limited logo

Beta Drugs Limited — Investor Relations & Filings

Ticker · BETA ISIN · INE351Y01019 LEI · 984500A89888DB9E6T57 National Stock Exchange of India Manufacturing
Open in API
Filings indexed 431 across all filing types
Latest filing 2026-01-12 Proxy Solicitation & In…
Country IN India
Listing National Stock Exchange of India BETA

About Beta Drugs Limited

https://www.betadrugslimited.com

Beta Drugs Limited specializes in the development, manufacture, and marketing of oncology formulations. The company provides a comprehensive portfolio of anti-cancer drugs across various therapeutic segments, including cytotoxic injectables, lyophilized products, tablets, and capsules. Its manufacturing capabilities encompass a wide range of oncology treatments such as chemotherapy agents and supportive care medications. The organization operates advanced production facilities designed to meet international quality standards, focusing on high-potency active pharmaceutical ingredients and finished dosage forms. The company serves diverse markets through its own branded products and contract manufacturing services, aiming to provide affordable and high-quality cancer care solutions. Its core competency lies in its specialized focus on the oncology niche and its integrated approach to pharmaceutical production.

Recent filings

Filing Released Lang Actions
Shareholders meeting
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a detailed notice of an Extraordinary General Meeting (EGM) of Beta Drugs Limited. It includes multiple resolutions for shareholder approval, such as increasing authorized share capital, approving an Employee Stock Option Plan (ESOP), extending ESOP benefits to group companies, and approving a preferential issue of equity shares. The content is typical of a meeting notice that sets out the agenda and resolutions to be voted on by shareholders. It does not contain financial statements, audit opinions, earnings data, or management discussion and analysis. It is not a report or transcript but a formal meeting notice with proposed resolutions. Therefore, the document fits the category of a Proxy Solicitation & Information Statement (PSI), which includes materials sent to shareholders to provide information and request votes for meetings such as EGMs.
2026-01-12 English
General Updates
Capital/Financing Update Classification · 95% confidence The document is a communication addressed to the National Stock Exchange of India Limited's Listing Compliance Department. It concerns a revised update about the acquisition of a 66.09% stake by Beta Drugs Limited in Nivian Lifesciences Private Limited. The text includes details about the acquisition, the business focus of Nivian, financial figures for the recent period, and strategic implications of the transaction. The document is relatively short (3651 characters) and is clearly an announcement or update about a financing or capital transaction rather than a full report or detailed financial statement. There is no indication of it being a full annual or interim report, audit report, or earnings release. It is not a regulatory filing in the sense of compliance or certification, nor is it a voting result or management change announcement. The content fits best with a Capital/Financing Update as it provides details on a significant acquisition transaction and stake purchase. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2026-01-11 English
General Updates
M&A Activity Classification · 95% confidence The document is an announcement of a definitive agreement for Beta Drugs Limited to acquire a majority stake in Nivian Lifesciences Private Limited. It details the transaction terms, business rationale, and strategic benefits of the acquisition. There is no indication of this being a full report, financial statement, or regulatory filing beyond the transaction announcement. The content fits the definition of M&A Activity, which covers announcements and documents related to merger proposals or takeover bids.
2026-01-10 English
Outcome of Board Meeting
Capital/Financing Update Classification · 95% confidence The document is a detailed disclosure made by Beta Drugs Limited to the National Stock Exchange of India under Regulation 30 of the SEBI Listing Obligations and Disclosure Requirements (LODR). It reports multiple board decisions including increasing authorized share capital, adoption of an employee stock option plan, and a significant acquisition transaction involving the purchase of 66.09% equity in another company. It also mentions the issuance of shares on a preferential basis as consideration for the acquisition and the convening of an extraordinary general meeting (EGM) for shareholder approval. The content is focused on corporate actions related to capital changes, stock option plans, and acquisition transactions, with detailed terms and regulatory compliance disclosures. This fits the category of Capital/Financing Update (CAP) because it involves changes in capital structure, stock option issuance, and acquisition financing. It is not an Annual Report, Earnings Release, or Management Report as it lacks financial statements or performance analysis. It is not a Proxy Solicitation or Voting Results announcement, nor a Merger & Acquisition filing in the strict sense of merger proxy statements or tender offers. The document is substantive and lengthy (15,000 characters), so it is not a mere announcement of a report publication. Therefore, the best classification is Capital/Financing Update (CAP).
2026-01-09 English
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Regulatory Filings Classification · 95% confidence The document is a confirmation certificate issued under Regulation 74(5) of the Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018. It confirms the dematerialisation of securities for the quarter ended 30th September 2025. The document is a compliance certificate issued by a registrar and transfer agent (MUFG Intime India Private Limited) to the company (Beta Drugs Limited). It does not contain financial statements, management discussion, or detailed financial data. It is a regulatory compliance confirmation related to securities dematerialisation, not a financial report or announcement of voting results. The document length is short (1942 characters) and it serves as a certification letter for regulatory compliance. According to the rules, such certification letters fall under Regulatory Filings (RNS).
2026-01-07 English
Trading Window
Regulatory Filings Classification · 95% confidence The document is an official communication to the stock exchange regarding the continuation of the trading window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015. It mentions the upcoming board meeting to consider price sensitive matters including acquisition and ESOP approval. The document is a regulatory announcement about trading restrictions and does not contain financial results, detailed financial data, or a report itself. It is not a report publication announcement since it does not mention any report being attached or published. It is not a management or earnings report, nor a capital/financing update directly, but rather a compliance notification related to insider trading regulations. Therefore, the best fitting category is Regulatory Filings (RNS).
2026-01-06 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.